Special Issue "Respiratory and Nasal Drug Delivery"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (20 December 2013)
Dr. Remigius U. Agu
Biopharmaceutics and Drug Delivery Laboratory, Dalhousie University, Halifax NS, Canada
Interests: respiratory/nasal; transporters; toxicity screening; drug delivery
Novel developments in the fields of Biotechnology and Combinatorial Chemistry rekindled overall interest in exploring the respiratory and nasal routes for systemic delivery of biomolecules (e.g., proteins, peptides and nucleic acids). Pursuits in these areas of drug delivery are not limited to macromolecules and systemic delivery. Many research groups are consistently looking for more effective ways to deliver small molecules local to the lung, nasal sinuses and brain via the nasal route. Novel approaches for efficient systemic and local drug delivery have been developed over the past few years. Such strategies include novel formulations (micro/nano particles, stent) and delivery devices. Successful respiratory and nasal drug delivery also requires sound experimental methods/model development. This special issue entitled: "Respiratory and Nasal Drug Delivery" will deal with key aspects of modern respiratory and nasal delivery. Micro-/nano-particulate delivery; formulation/delivery of aerosols and dry powders; optimization of nasal and respiratory drug absorption using in vitro, ex vivo and in situ tissue culture and animal models; brain targeting via the nasal route; exploration of mechanisms of epithelial drug permeation (e.g., active transport mechanisms); aerosol delivery simulation and other particle projectile studies; toxicological aspects of nasal and respiratory drug delivery, especially micro and nanoparticles; pharmacodynamics and pharmacokinetics of novel formulations following nasal and inhalational administration will be covered. Other relevant topics including muco-/bio-adhesive delivery, cilio-toxicity screening, delivery devices development, optimization and validation are also welcomed.
Dr. Remigius U. Agu
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- drug delivery
- drug targeting
Review: Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives
Pharmaceutics 2014, 6(3), 378-415; doi:10.3390/pharmaceutics6030378
Received: 18 February 2014; in revised form: 20 June 2014 / Accepted: 24 June 2014 / Published: 10 July 2014| PDF Full-text (1638 KB) | HTML Full-text | XML Full-text
Article: Preliminary Studies on Validation of Calu-3 Cell Line as a Model for Screening Respiratory Mucosa Irritation and Toxicity
Pharmaceutics 2014, 6(2), 268-280; doi:10.3390/pharmaceutics6020268
Received: 26 January 2014; in revised form: 29 May 2014 / Accepted: 3 June 2014 / Published: 13 June 2014| PDF Full-text (202 KB) | HTML Full-text | XML Full-text
Review: Drug-Eluting Nasal Implants: Formulation, Characterization, Clinical Applications and Challenges
Pharmaceutics 2014, 6(2), 249-267; doi:10.3390/pharmaceutics6020249
Received: 26 January 2014; in revised form: 28 March 2014 / Accepted: 7 May 2014 / Published: 27 May 2014| PDF Full-text (582 KB) | HTML Full-text | XML Full-text
Review: Analytical Challenges and Regulatory Requirements for Nasal Drug Products in Europe and the U.S.
Pharmaceutics 2014, 6(2), 195-219; doi:10.3390/pharmaceutics6020195
Received: 20 December 2013; in revised form: 24 March 2014 / Accepted: 31 March 2014 / Published: 11 April 2014| PDF Full-text (5473 KB) | HTML Full-text | XML Full-text
Concept Paper: An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation
Pharmaceutics 2014, 6(1), 175-184; doi:10.3390/pharmaceutics6010175
Received: 5 November 2013; in revised form: 22 January 2014 / Accepted: 13 February 2014 / Published: 21 March 2014| PDF Full-text (245 KB) | HTML Full-text | XML Full-text
Article: Performance of Dry Powder Inhalers with Single Dosed Capsules in Preschool Children and Adults Using Improved Upper Airway Models
Pharmaceutics 2014, 6(1), 36-51; doi:10.3390/pharmaceutics6010036
Received: 20 December 2013; in revised form: 20 January 2014 / Accepted: 23 January 2014 / Published: 6 February 2014| PDF Full-text (366 KB) | HTML Full-text | XML Full-text
Article: Electrostatic Charge Effects on Pharmaceutical Aerosol Deposition in Human Nasal–Laryngeal Airways
Pharmaceutics 2014, 6(1), 26-35; doi:10.3390/pharmaceutics6010026
Received: 13 September 2013; in revised form: 23 January 2014 / Accepted: 26 January 2014 / Published: 29 January 2014| PDF Full-text (1346 KB) | HTML Full-text | XML Full-text
Last update: 28 May 2014